Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $247

HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $251 to $247.

byBenzinga Newsdesk

August 9, 2021

1 minute read

HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $251 to $247.

Inspire Medical Systems Q2 EPS $(0.48) Beats $(0.64) Estimate, Sales $52.96M Beat $43.87M Estimate

By Benzinga Newsdesk

August 3, 4:39 PM

Inspire Medical Systems (NYSE:INSP) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.64) by 25 percent. This is a 45.45 percent increase over losses of $(0.88) per share

INSP

Kantaro’s Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order. BZ NOTE: Kantaro Is A Joint Venture Between Mount Sinai Health System, RenalytixAI And Bio-Techne

By Benzinga Newsdesk

June 2, 11:36 AM

Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ:RNLX), and its commercial partner Bio-Techne Corporation (NASDAQ:TECH), have received Health Canada

RNLX